BARDA are reimbursing the company for the costs of the burns trial. As % of revenues it's still actually significant so it's worth remembering. OTH revenues are revenues and if the trial is successful it will result in more actual sales and probably open the door to reimbursement for more patients.
Ann: FY24 Trading Result (unaudited), page-172
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.07 |
Change
0.030(1.47%) |
Mkt cap ! $1.429B | |||
| Open | High | Low | Value | Volume |
| $2.11 | $2.12 | $2.05 | $2.783M | 1.335M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 19976 | $2.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.07 | 9633 | 3 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| PNV (ASX) Chart |